Metastasis depends on the ability of tumor cells to establish a relationship with the newly seeded tissue that is conducive to their survival and proliferation. However, the factors that render tissues permissive for metastatic tumor growth have yet to be fully elucidated. Breast tumors arising during pregnancy display early metastatic proclivity, raising the possibility that pregnancy may constitute a physiological condition of permissiveness for tumor dissemination. Here we have shown that during murine gestation, metastasis is enhanced regardless of tumor type, and that decreased NK cell activity is responsible for the observed increase in experimental metastasis. Gene expression changes in pregnant mouse lung and liver were shown to be similar to those detected in premetastatic sites and indicative of myeloid cell infiltration. Indeed, myeloid-derived suppressor cells (MDSCs) accumulated in pregnant mice and exerted an inhibitory effect on NK cell activity, providing a candidate mechanism for the enhanced metastatic tumor growth observed in gestant mice. Although the functions of MDSCs are not yet understood in the context of pregnancy, our observations suggest that they may represent a shared mechanism of immune suppression occurring during gestation and tumor growth.
Introduction
Metastasis is a multistage process that constitutes the primary cause of cancer-related death. It requires cells to detach from the primary tumor mass, migrate toward and invade lymphatic or blood vessels, survive within the circulation, attach to the endothelium of distant organs, penetrate the endothelial barrier, and establish new tumor colonies (1) . The process is highly inefficient, as less than 0.1% of tumor cells that penetrate the circulation end up forming metastatic colonies (2, 3) , but the explanation for the observed inefficiency of metastasis is still largely obscure. Several possible reasons have been invoked, including tumor cell destruction by shear stress and immune cells in the circulation (4) , and it is clear that large numbers of tumor cells can penetrate distant organs only to undergo apoptosis or enter a state of dormancy that may extend for an indefinite period of time (5) . Mechanisms underlying dormancy are unclear, although recent observations suggest that the new microenvironment may prevent tumor cells from proliferating while allowing them to survive, or, alternatively, that immune surveillance may keep micrometastases in check (6) . Over time, modifications in the host microenvironment -including the recruitment and function of cells of the immune system -that occur as a result of a variety of physiological events, including aging, may relieve the pressure on the metastatic foci, allowing them to expand and ultimately form clinically relevant macrometastases (7) .
Recent evidence suggests that tumor cells may be able to direct the formation of premetastatic niches in selected organs by secreting or by inducing stromal cell secretion of cytokines or growth factors -collectively described as tumor-derived soluble factors (TDSFs) -that render selected target organ microenvironments permissive for the implantation and subsequent outgrowth of disseminating tumor cells (8, 9) . A major constituent of premetastatic niches are bone marrow-derived cells (BMDCs), which promote local tumor cell establishment by secreting chemoattractants (10, 11) , producing proteases that facilitate tumor cell infiltration of the target organ and elaborating extracellular matrix components that further help recruit BMDCs or tumor cells to these sites (9, 12) . Enhanced lung metastasis may also result from experimental allergen-induced lung leukocyte infiltration and asthma has been shown to be prevalent in breast cancer patients with lung metastases (13) .
Tumors also need to escape immune surveillance to grow at primary as well as at metastatic sites (14) . One of the possible results of immunoediting, a process that shapes tumor cell immune resistance by selective pressure of the immune system itself, is the accumulation of cells of the myelomonocytic lineage that harbor immunosuppressive functions and repress antitumor immunity. This heterogeneous cell population of myeloid-derived suppressor cells (MDSCs) expands not only in the context of cancer (driven by TDSFs), but also during situations such as infection, autoimmune disease, vaccination, and trauma (15, 16) .
Pregnancy is a physiological state of dampened cellular immunity in the context of maternal immune tolerance toward the semiallogenic conceptus (17) . Several mechanisms are involved in preventing rejection of fetal tissues, including, among others, lack of classical class I MHC molecules on the surface of fetal cells, expression of NK cell-and T cell-modulating HLA-G molecules, hyporesponsiveness of immune cells as a result of indoleamine 2,3-dioxygenase activity and specific silencing of alloreactive T cells by regulatory T cells (18) . MDSC activity, however, has not been invoked in this context. Pregnancy-associated cancers (usually defined as malignancies diagnosed during pregnancy or within 1 year of parturition) do not generally differ in outcome, although there is some debate in the case of melanomas. However, the worse prognosis of pregnancy-associated breast cancer (PABC) is widely recognized but the underlying mechanisms remain obscure. Explanations including delayed diagnosis and putative tumor-promoting properties of the involuting mammary gland (19) have been proposed to result in increased stage at diagnosis. A relationship between enhanced metastatic proclivity of PABC and decreased cellular immunity has been suggested, but without firm experimental support so far (20) .
A mouse model of increased experimental metastasis during gestation has been described (21) , where the difference compared with nonpregnant littermates was ascribed to increased platelet-tumor cell aggregation that promotes tumor cell survival and hence enhances metastatic growth. Our present observations indicated that murine gestation augmented the rate and the degree of tumor dissemination, regardless of tumor cell origin. Moreover, we showed that decreased NK cell numbers and cytotoxicity led to blunted local clearing of tumor cells and demonstrated that MDSCs contributed to the reduced NK activity and corresponding enhancement of tumor dissemination. Furthermore, we provided evidence that pregnancy induced metastasis-promoting changes in the lung and liver microenvironment, as revealed by the striking similarities between gene expression profiles of pregnant mouse organs and premetastatic organs in cancer-bearing mice.
Results
Pregnant mice develop a greater number of metastases than do their virgin counterparts upon i.v. injection of B16.F10 melanoma cells. B16.F10 melanoma cells were engineered to stably express firefly luciferase and were injected into the tail vein of 16-day pregnant and virgin NOD/SCID mice. Tumor cell injection around day 16 of murine gestation has previously been shown to lead to maximal enhancement of metastasis load (21) . Biweekly bioluminescence imaging revealed a consistently higher tumor load in pregnant animals, culminating in 5-to 10-fold greater signal intensity than in virgin mice 17 days after tumor cell injection ( Figure 1A ). At this time point, mice were sacrificed, and examination at necropsy confirmed a strikingly greater tumor load in pregnant mice ( Figure 1 , B and C), consistent with the bioluminescence signals. In organs such as lungs that displayed metastatic colonies in both sets of animals, the size and frequency of the colonies were significantly greater in pregnant mice, as determined by quantifying metastatic lesions on lung sections (Figure 1 , D and E). In addition, organs including liver and abdominal lymph nodes that were metastasisfree in virgin mice contained numerous metastases in the majority of pregnant animals ( Figure 1C ). Mammary glands in pregnant mice also harbored more metastases than in virgin animals, and in all organs, metastatic lesions tended to be larger in pregnant mice. Thus, the number, size, and degree of dissemination of tumor colonies were markedly increased during pregnancy.
Metastasis is enhanced in pregnant mice regardless of tumor cell type, mode of injection, and mouse strain. To determine whether the observed increase in B16.F10 cell dissemination in pregnant mice is a general or cell type-restricted phenomenon, we injected luciferase-expressing human fibrosarcoma HT1080 cells and melanoma MDA-MB-435 cells into the tail vein of virgin and 16-day pregnant immunocompromised NOD/SCID mice and assessed metastasis development over a 30-to 50-day period after injection ( Figure 2 , A-D, and Supplemental Figure 1 , A-D; supplemental material available online with this article; doi:10.1172/JCI41936DS1). Similar to experiments using B16.F10 cells, pregnant mice bearing HT1080 and MDA-MB435 cells displayed significantly higher bioluminescence, which reflected a greater number and size of lung metastases from both cell lines. When the mouse lymphoma cell line Yac-1 was tested in experimental metastasis assays, pregnant NOD/SCID mice also had increased tumor cell load and succumbed earlier than virgin mice (Supplemental Figure 1E) . Finally, tail vein injection of luciferase-expressing TA3 mouse mammary carcinoma cells into syngeneic, fully immunocompetent virgin or pregnant A/Jax mice, as well as injection of B16.F10 cells into C57BL/6 mice, attested that increased experimental metastasis in pregnant mice was not restricted to a given cell line, tumor type, mouse strain, or immunocompromised background (Figure 2 , E-H, and see below).
Whereas the experimental metastasis model based on tail vein injection of tumor cells allowed demonstration of the difference in late-stage metastatic tumor growth, it did not provide evidence that development of spontaneously occurring metastases was affected. We therefore selected a model in which this issue could be addressed in vivo. Lewis lung carcinoma (LCC) cells were injected s.c. into syngeneic virgin mice, and half the animals were mated within hours of injection. After 11 days, primary tumors had reached 8-9 mm in diameter and were surgically resected, and the metastasis load was monitored biweekly by bioluminescence imaging ( Figure 2I) . Consistent with what was observed after tail vein injection, a greater signal intensity was recorded in pregnant mice, corresponding to a larger size of lung metastases in a higher number of animals at necropsy (Figure 2 , J and K). Similar results were obtained using B16.F10 cells in C57BL/6 mice (data not shown)
Pregnancy does not affect in vitro and in vivo tumor cell growth. To address the possible effects of pregnancy-associated circulating factors on the observed differences in tumor cell dissemination, we determined the expression of estrogen receptor (ER) and progesterone receptor (PR) on B16.F10, HT1080, MDA-MB-435, TA3, and LLC cells. Immunohistochemical analysis of lung metastases derived from the 5 cell lines failed to reveal detectable expression of either hormone receptor (Supplemental Figure 2A) . We next assessed the response of the tumor cell lines to serum from virgin and pregnant NOD/SCID mice. As expected, mouse serum-stimulated cell proliferation compared to that of serum-free culture medium ( Figure 3A ). However, there was no significant difference between the effect of serum derived from virgin and pregnant mice in the case of B16.F10 and HT1080 cells; with MDA-MB435 and Yac-1 cells, pregnant mouse-derived serum had a weaker effect on tumor cell proliferation than did serum from virgin mice. Similar observations were made when plasma extracted from pregnant or virgin mice was used (data not shown). To compare primary tumor growth, B16.F10, HT1080, and MDA-MB435 tumor cells were injected s.c. into virgin and 4-day pregnant NOD/SCID mice, and tumor growth was assessed 12 days later. Similarly, s.c. injection of 5 × 10 5 LLC cells into virgin C57BL/6 mice was done immediately before breeding, and tumor growth was monitored for 11 days before resection. No significant difference was found in tumor size between pregnant and virgin animals ( Figure 3B ). Finally, staining of lung sections from virgin and pregnant mice 3, 6, and 10 days after tail vein injection of the MDA-MB-435 cell line failed to reveal differences in the number of cells expressing the (human) proliferation marker Ki67 (Supplemental Figure 2B) . Taken together, these findings argue against a purely growth-promoting effect of pregnancy on the injected tumor cells.
Tumor cell clearance from lungs after tail vein injection is distinct in virgin and pregnant mice. Based on the observations that in vitro growth and s.c. tumor forming capacity of the cells used in these experiments were unaffected by circulating factors associated with pregnancy, we reasoned that the explanation for the observed enhancement of disseminated tumor growth in experimental metastasis assays is most likely related to changes specifically affecting circulating tumor cells or those immobilized in the target organs. To address factors that may enhance permissiveness for tumor dissemination during pregnancy, we sought to determine the time point at which a disparate evolution could first be detected, eventually leading to the massive difference in tumor load at necropsy. GFP-expressing HT1080 cells (1-2 × 10 6 cells) were injected i.v. into virgin and 16-day pregnant NOD/SCID mice, and fluorescence stereomicroscopy was performed on lungs 1, 6, and 24 hours as well as 4 days following injection. After initially comparable lung fluorescence in both conditions, signal intensity began to diminish in virgin compared with pregnant mice as early as 6 hours after injection (Figure 4) . The difference was clear at 24 hours; by 4 days, there was virtually no fluorescent signal from lungs of virgin mice, whereas the signal from lungs of pregnant mice Figure 5A ). Whereas NK cells represented a lower percentage of total leukocytes in the spleen and blood of pregnant mice than that in virgin mice, the proportions in lung and liver were comparable, albeit with a tendency to decrease in pregnant mice as well ( Figure 5 , B and C). The slight decrease of the NK cell population in the liver and lung of pregnant mice could also be appreciated on frozen sections using an anti-NKp46 antibody (Supplemental Figure 4A) .
The importance of NK cell function in controlling metastasis has long been recognized (22) . However, to our knowledge, no direct link has been established between decreased NK numbers and function in pregnant mice and increased experimental metastasis. We therefore investigated whether depletion of NK cells might abolish the difference in metastasis load between pregnant and virgin NOD/SCID mice. We used 3 different strategies of NK cell depletion ( Figure 5D ): nonspecific leukocyte depletion by sublethal whole-body irradiation, which reduced NK cell counts in peripheral blood of virgin and 16-day pregnant NOD/SCID mice about 30-fold; specific NK cell depletion by anti-asialo GM1 (AAGM1) antibody, which resulted in a 4-fold (pregnant) to 15-fold (virgin) reduction in NK cell counts; and use of Il-2 receptor common γ subunit knockout (cg KO) NOD/SCID mice, which had no NK development at all. Upon B16.F10 tumor cell injection, the absence (cg KO mice) or near-complete depletion (irradiated mice) of NK cells resulted in overall increased metastasis take ( Figure 5E ), with liver metastases developing in virgin animals as well, and in the abrogation of any difference in tumor cell load between pregnant and virgin NOD/SCID mice. Consistent with this notion, virgin and pregnant cg KO NOD/SCID mice developed comparable metastatic disease upon tail vein injection of HT1080 and MDA-MB-435 tumor cells ( Figure 5 , F and G). Similarly, fluorescence stereomicroscopy of lungs of 16-day pregnant and virgin cg KO NOD/SCID mice at different time points after the injection of GFP-expressing HT1080 cells showed very limited tumor cell clearance from the lung microvasculature in the absence of NK cells and, more importantly, no difference between pregnant and virgin animals (Supplemental Figure 4B) . However, AAGM1-treated virgin mice still developed significantly less metastases than did their pregnant counterparts, despite a greater reduction in NK numbers ( Figure 5, D and E ). It appears, therefore, that changes in NK cell cytotoxicity -and not merely decreased NK cell numbers -may be primarily responsible for enhanced B16.F10 metastasis in pregnant NOD/SCID mice. To determine NK activity, standard 51 Cr release assays were performed on Yac-1 target cells using splenocytes extracted from poly(I:C)-stimulated 16-day pregnant or virgin NOD/SCID mice. Flow cytometry -adjusted for NK proportions among splenocytes -revealed an approximately 8-fold reduction in mean NK cell cytotoxicity in splenocytes derived from pregnant mice ( Figure 5H ). Taken together, these observations suggest that the mechanism whereby pregnancy leads to increased experimental metastasis is related to reduced NK cell-mediated clearance of tumor cells within hours of their injection.
NK cell impairment underlies increased metastasis in pregnant immunocompetent C57BL/6 mice. Whereas use of NOD/SCID mice in this experimental metastasis model had the advantage of facilitating the elucidation of the role of innate immunity in mediating increased metastasis in pregnant mice as well as allowing xenografting of human tumor cell lines, the involvement of an immune-based mechanism warranted validation in a more physiological context using immunocompetent C57BL/6 mice. Injection of syngeneic B16.F10 melanoma cells i.v. into 16-day pregnant and virgin C57BL/6 mice led to an overall higher metastasis load in pregnant animals ( Figure 6A ), similar to the difference observed in NOD/SCID mice.
B16.F10 melanoma cells were originally isolated from C57BL/6 mice and have been reported to be sensitive to NK cell killing. In order to address the question of how much of the difference in metastasis development can be ascribed to reduced NK function in pregnant C57BL/6 mice, we repeated the experiment with the syngeneic lymphoma cell lines RMA and EL4, which are both known to be resistant to NK cell-mediated cell cytotoxicity. The difference in metastasis take between pregnant and virgin mice was greatly reduced and did not reach statistical significance when these 2 cell lines were used ( Figure 6 , B and C). Nevertheless, a residual increase in tumor cell load was still apparent, possibly indicating that factors other than NK function -such as suppressed T cell activity -are implicated in increasing metastasis take in immunocompetent pregnant mice. Using flow cytometry, we found no significant difference in NK cell proportions in blood, spleen, and lung of 16-day pregnant C57BL/6 mice (Supplemental Figure 5 ). Decreased NK cell cytotoxicity in pregnant C57BL/6 mice was also confirmed using splenocytes in a standard 51 Cr release assay ( Figure 6D ).
MDSC accumulation in pregnant mice contributes to increased host permissiveness to metastasis.
Whereas dampened cellular immunity is an acknowledged feature of pregnancy-associated immune adaptation, little is known about how systemic NK cell function is regulated during pregnancy (17) . On the other hand, MDSCs have previously been shown to inhibit NK cytotoxicity in tumor-bearing mice as well as in cancer patients (23) (24) (25) . We therefore assessed whether the well-known expansion of granulocytic populations and increased leukocyte counts associated with pregnancy (26) could reflect, at least in part, the accumulation of such immunosuppressive cells. In mice, MDSCs are characterized by coexpression of CD11b and Gr-1 (27) . Using flow cytometry, we found that spleen, peripheral blood, lung, and liver of pregnant NOD/SCID mice harbored significantly higher proportions of CD11b hi Gr-1 + cells than did those derived from virgin mice ( Figure 7A ). Similar observations were made upon Gr-1 staining of lung and liver sections (Supplemental Figure 6A) . CD11b hi Gr-1 hi subsets constituted the major expanded fraction ( Figure 7B ), which could further be characterized as Ly-6C -Ly-6G + cells (Supplemental Figure 6B) . Accumulation of these cells with granulocytic morphology was also evident on blood smears and differential white blood cell counts (compare with control animals in Supplemental Figure 6I) . Similarly, increased granulocyte proportions were detected in pregnant C57BL/6 mice, and CD11b hi Gr-1 + cells -in particular, CD11b hi Gr-1 hi fractions -accumulated in blood and spleen of these animals compared with their virgin counterparts (Supplemental Figure 6, C-E) . Finally, the 3 cell populations consisting of NK, CD11b hi Gr-1 hi , and CD11b hi Gr-1 lo cells were monitored in the circulation throughout NOD/SCID gestation and in littermate virgin mice in parallel, beginning 3 days after mating and ending 4 days after parturition in the former, with examination of a blood sample every 3-4 days. In order to avoid confounding factors that may be caused by repetitive blood sampling in an animal, the results were expressed as a ratio of pregnant to virgin mouse cell population. MDSC (CD11b hi Gr-1 hi more than CD11b hi Gr-1 lo ) levels rose during pregnancy, reaching a peak around day 14, and remained elevated for at least 4 days after parturition. NK levels started dropping from around day 6 of pregnancy, reaching a nadir just before parturition, and returned to normal proportions within days after giving birth (Supplemental Figure 6F) . Since MDSCs are defined not only by their double-positive staining for CD11b and Gr-1, but also -and more importantly -by their functional capacity to inhibit cellular immunity and especially T cell function, we cocultured CD11b hi Gr-1 hi cells extracted from pregnant and virgin C57BL/6 spleens using Ly-6G-coated magnetic microbeads with T cells purified from spleen and lymph nodes of virgin C57BL/6 mice using CD90.2-coated magnetic microbeads. T cells that were in contact with Ly-6G + cells from pregnant mice displayed up to 4-fold suppressed proliferation dependent on T cell/MDSC ratios, as assessed by 3 H-thymidine incorporation and CFSE labeling assays ( Figure 7C and Supplemental Figure 6G ). Accordingly, Il-2 secretion was reduced by 30% compared with T cells that were cocultured with virgin mouse-derived Ly-6G + cells (Supplemental Figure 6H) . Of note, Ly-6G + cells from virgin mice also suppressed proliferation and Il-2 secretion of T cells compared with T cells that had not been cocultured, albeit to a much lesser extent than pregnant mouse-derived MDSCs, suggestive of some immunoregulatory properties of Ly-6G + cells derived from naive mice as well. IFN-γ was slightly diminished in T cells exposed to pregnant compared with virgin Ly-6G + cells, whereas there was no difference in Il-10 production (data not shown).
We next investigated whether CD11b hi Gr-1 hi cells contribute to reduced NK cell cytotoxicity in pregnant NOD/SCID mice. Ly-6G + cells extracted from pregnant and virgin NOD/SCID splenocytes (Supplemental Figure 6B ) and NK cells isolated from naive NOD/ SCID female spleens using CD49b-coated magnetic microbeads were cocultured before subjecting the cell mix to standard 51 Cr release cytotoxicity assays using Yac-1 target cells. NK cells exposed to Ly-6G + MDSCs from pregnant mice exhibited approximately 33% reduced cytotoxicity ( Figure 7D ).
To determine the functional effect of MDSCs on metastasis, we depleted virgin and pregnant mice of these cells using anti-Gr1 RB6-8C5 antibody. Peripheral blood smears immediately preceding B16.F10 tumor cell injection revealed robust depletion of granulocyte fractions (Supplemental Figure 6I) . Injection of tumor cells after MDSC depletion resulted in unaltered metastasis in virgin mice, but significantly reduced metastasis in pregnant mouse lungs (Figure 7 , E and F, and Supplemental Figure 6I) . Conversely, adoptive transfer of Ly-6G + spleen-derived cells prior to Yac-1 tumor cell injection resulted in increased metastasis load in animals receiving MDSCs isolated from pregnant NOD/SCID mice compared with those receiving Ly-6G + cells from virgin mice (Supplemental Figure 6K) .
Gene expression profiles of pregnant and virgin mouse lung and liver reveal similarities to premetastatic niche signatures and predict outcome of patients with lung cancer.
In parallel to investigating changes in the immune system that favor tumor cell dissemination during murine gestation, we sought to determine whether pregnancy also affects the target organ microenvironments, thereby generating a more metastasispermissive "soil." We assessed gene expression profile changes in the lung and liver of 16-day pregnant mice compared with virgin littermates using the Affymetrix mouse 430 chip. Setting the false discovery rate (FDR) at 5%, our analysis revealed up-and downregulation of 141 and 147 unique genes, respectively, in the lungs of pregnant NOD/SCID mice, and of 352 and 389 genes, respectively, in the liver of pregnant animals (Supplemental Table 1 ). Interestingly, of the 141 genes observed to be upregulated in pregnant mouse lungs, 13 were shared (P = 4.1 × 10 -20 , Figure 8A ) with the 50 top upregulated probesets in premetastatic lungs as published by Hiratsuka et al. (10) : cyclin-dependent kinase inhibitor 1A/P21 (Cdkn1a); cathelicidin antimicrobial peptide (Camp); IL-1 receptor, type II (Il1r2); lysyl oxidase (Lox); matrix metallopeptidase 8 (Mmp8); C-type lectin domain family 4, member d (Clec4d); neutrophilic granule protein (Ngp); S100 calcium binding protein A8/calgranulin A (S100a8); S100 calcium binding protein A9/calgranulin B (S100a9); solute carrier family 2, member 3 (Slc2a3); schlafen 4 (Slfn4); elastin microfibril interfacer 2 (Emilin2); and cDNA sequence BC055107. The term premetastatic niche has been coined to describe a situation of increased metastatic permissiveness in organs of mice bearing aggressive primary tumors. Premetastatic niches are associated with the recruitment of bone marrow-derived cells (BMDCs), which are believed to play a key role in their establishment (9, 12) . Upregulated genes common to pregnant and premetastatic lungs included several that encode myeloid cell-derived proteins. Lox, which has been proposed to be an essential constituent of premetastatic niches (12) and is functionally involved in BMDC recruitment, displayed a robust induction in the lungs of pregnant mice as determined by quantitative RT-PCR ( Figure 8B ).
In parallel, gene expression profiling of pregnant mouse livers and comparative database analysis revealed significant overlaps among up-and downregulated genes in pregnant mouse liver tissue and previously described premetastatic livers from animals bearing xenotransplanted cecal tumors (ref. 28 , Figure 8C , and Supplemental Figure 7A ). Not surprisingly, there was a significant overlap in up-and downregulated genes between pregnant mouse lungs and liver ( Figure 8D , Supplemental Figure 7B , and Supplemental Table  2 ), and several of the shared upregulated genes could be associated with infiltration of myeloid cells -possibly MDSCs. Finally, the prognostic value of differentially expressed genes in pregnant mouse lungs was tested on lung cancer microarray data for which patient outcome was available (29) . This analysis was based on the hypothesis that stromal components -including immune cells -play an important role in primary tumor progression and are represented in transcriptome analyses of bulk tumor samples. Unsupervised hierarchical clustering of lung squamous cell and adenocarcinoma gene expression data (29) revealed that the downregulated genes in pregnant mouse lungs were able to divide patients into good-and poor-prognosis groups ( Figure 8E ). Mean fold change of each of the 91 human orthologs of downregulated genes in pregnant mouse lungs was evaluated in both patient groups, and 51 (59%) of these genes showed lower expression levels in poor-prognosis patients (P = 0.0046).
Discussion
We have shown that murine gestation is associated with enhanced permissiveness for metastasis and that a candidate underlying mechanism is decreased NK cytotoxicity in the presence of an increased MDSC population. Although pregnancy, and multiple pregnancies in particular, confers protection against breast cancer development later in life (30) , breast tumors that occur during pregnancy itself or within 5 years of giving birth display a high degree of aggressiveness, with rapid dissemination and metastasis (31) . Mammary gland involution has been suggested to be accompanied by tumor-promoting proinflammatory processes that could accelerate the initial steps of the metastatic cascade, including invasion and angiogenesis (32) . However, pregnancy and related systemic adaptations could also contribute to increased tumor dissemination by facilitating later steps of the metastatic cascade, that is, once tumor cells have reached the lymphatic or blood circulation.
The only experimental work addressing specific metastasis-enhancing mechanisms in gestant mice has come to the conclusion that platelets from pregnant mice display greater and irreversible aggregability that increases survival of injected tumor cells and leads to greater metastasis load (21) . However, adoptive transfer of platelets isolated from pregnant mice could only marginally enhance metastasis load in virgin mice (21) . Accordingly, when we treated pregnant and virgin NOD/SCID mice with low-molecular weight heparin (LMWH) prior to tumor cell injection -at doses previously shown to abrogate tumor cell-induced thrombocytopenia, a measure for tumor cell-induced platelet aggregation (33) -we could only mar- ginally decrease B16.F10 and HT1080 metastasis in pregnant mice (Supplemental Figure 8) . This observation argues against a major metastasis-promoting effect of gestation-induced changes in tumor cell platelet aggregation, or the coagulation cascade, for that matter. In addition, neither serum nor plasma derived from pregnant mice had any direct positive effect on tumor cell proliferation, nor did s.c. tumors display differential growth. It therefore seemed more likely that the explanation for increased tumor dissemination during pregnancy lies in an altered tumor-host relationship. Because establishment of a relationship with host tissues that is conducive to tumor cell survival and proliferation is key for metastatic development, the observed permissiveness for tumor dissemination displayed by tissues during pregnancy may provide clues as to the identity of host factors that regulate tumor metastasis in general.
The obvious candidates among host factors that may determine metastatic tumor growth are the physical and chemical properties of tissues themselves and the state of the innate and adaptive immunity. Our observation of a rapid, but differential, clearing of tumor cells from the lung microvasculature of NOD/SCID mice, with the persistence of more tumor cells during gestation, suggests a role for innate immunity. Although immunodeficient NOD/SCID mice were used in most experiments conducted in the present study, immunodeficiency is not a prerequisite for increased metastasis in pregnant mice, since similar observations were made in fully immunocompetent A/Jax mice injected with syngeneic TA3 mammary carcinoma cells or with C57BL/6 mice challenged with B16 melanoma cells (ref. 21 and the present study). Furthermore, metastasis was also enhanced in a spontaneous metastasis assay, most likely through promotion of the late steps of the metastatic cascade. It is well established that NK cells are among the main effectors of innate antitumor immune surveillance, and their importance in controlling tumor dissemination is widely accepted (22) . On the other hand, pregnancy is a state of dampened cellular immunity, and NK activity in particular has been suggested to be decreased during murine (34) as well as human (35) (36) (37) pregnancies. Accordingly, we found a decrease in NK cell proportions in blood, spleen, lungs, and liver of 16-day pregnant mice and greatly reduced NK cell cytotoxicity. The total absence of NK cells in cg KO mice or the resistance of tumor cells to NK killing abolished the difference in metastasis growth between virgin and pregnant mice. Of note, although specific -but incomplete -NK cell depletion by AAGM1 antibody increased overall metastasis load, pregnant mice still developed more metastases than did their virgin counterparts, despite the persistence of more NK cells in the former. This finding suggests that decreased NK cell effector function, rather than merely decreased NK cell numbers, is responsible for enhanced tumor dissemination. We therefore provide the first evidence to our knowledge that the pregnancy-related decrease in systemic NK cell activity is responsible for the enhancement of host permissiveness to metastasis during murine gestation and may contribute to the worse prognosis of PABC, as hypothesized previously (20) .
Why systemic NK cell activity decreases during pregnancy is unclear. It is possible that NK cell function is directly affected by the increased levels of steroid hormones during pregnancy (38) or that placenta-derived microparticles (17) , exosomes (39) , or soluble molecules such as sHLA-G (40) regulate their activity. Alternatively, pregnancy-related circulating factors could induce immunomodulatory changes in the microenvironment of target organs of metastasis. We therefore addressed possible mechanisms by investigating transcriptome changes that occur during pregnancy. Gene expression profile analysis revealed that lungs and liver from pregnant mice bore striking similarities to lung (10) and liver (28) premetastatic niche signatures. Commonly upregulated genes in pregnant and tumor-bearing mouse lung include Lox and several genes associated with myeloid cell recruitment. LOX is secreted by hypoxic breast tumors and accumulates in the lungs of tumor-bearing animals prior to tumor cell dissemination, where it modifies basement membranes and contributes to BMDC recruitment (12, 41) . Primary tumors are known to elaborate soluble factors (i.e., TDSFs) that drive the formation of privileged sites for the engraftment of disseminating tumor cells; moreover, TDSFs have been shown to orchestrate the expansion and activation of myeloid cell precursors that display suppressive activity for both adaptive and innate immunity (16) . These MDSCs are characterized by double-positive CD11b and Gr-1 staining in mice and accumulate in the primary tumor, tumor-draining lymph nodes, spleen, and lung of tumor-bearing animals. However, they have not been suggested to be constituents of premetastatic niches.
Premetastatic niches are characterized by the accumulation of BMDCs (42) that have further been characterized as CD11b + cells (9, 10, 12) or Gr-1 + cells (28) . To our knowledge, no experimental work thus far has shown an immunosuppressive function of these myeloid cells recruited to premetastatic sites, although a recent review raises the point that BMDCs may create "immune sanctuary sites" that favor survival and proliferation of engrafted metastatic cells (8) . We provide evidence that CD11b hi Gr1 + cells -in particular CD11b hi Gr-1 hi subsets -accumulate in pregnant mouse blood, spleen, lung, and liver, raising the possibility that the corresponding immunosuppressive activity may have a blunting effect on NK cell function. The anti-Gr-1 antibody recognizes 2 distinct epitopes: Ly-6C, expressed on Gr-1 lo cells; and Ly-6G, expressed on the Gr-1 hi population. Gr-1 hi cells of granulocytic morphology isolated from pregnant mice using anti-Ly-6G magnetic microbeads inhibited T cell proliferation and Il-2 secretion in addition to decreasing NK cell cytotoxicity in vitro compared with cells extracted from their virgin counterparts. This immunosuppressive function strongly supports the notion that the myeloid cells accumulating during murine gestation are indeed MDSCs. Consistent with these observations, MDSCs isolated from tumor-bearing animals have been shown to decrease NK activity in a cell contact-dependent manner and to be responsible for increased tumor dissemination (24, 25) .
Finally, the observation that in vivo depletion of MDSCs using antiGr-1 antibody reduced metastatic tumor spread in pregnant mice, but not in virgin mice, confirms their mechanistic involvement in enhancing permissiveness to metastasis in pregnant mice. This finding and the results of the adoptive transfer experiment lend further support to the notion that Gr-1 + cells are functionally distinct in pregnant and virgin animals. This is in accordance with several reports that show immunosuppressive function of CD11b hi Gr1 + cells derived from tumor-bearing, but not tumor-free, mice (24, 43) .
Comparative analysis of differentially expressed genes of pregnant mouse lungs and liver and of premetastatic niches in organs of tumor-bearing mice (10, 28) revealed the upregulation of S100a8 and S100a9 in all 4 gene expression profiles, representing situations of enhanced metastatic growth. Hiratsuka and colleagues have shown how these chemoattractants produced by cells of the myeloid lineage not only recruit additional BMDCs, but also attract circulating tumor cells and enhance their invasiveness, thereby favoring lung colonization (10, 11) . On the other hand, these chemotactic molecules are important inflammatory mediators that have been shown to contribute to MDSC accumulation and function in primary tumors (44, 45) . The combined findings of S100a8 and S100a9 upregulation and MDSC accumulation in pregnant mouse lungs and liver further validate the hypothesis that MDSCs may participate in the elaboration of the premetastatic niche, thereby not only facilitating tumor progression at the primary site, but also enhancing the establishment of metastatic lesions.
In a clinical study, MDSC numbers have been shown to correlate with cancer stage and to influence prognosis (46) . As the gene expression profile of pregnant mouse lung is suggested to reflect the accumulation of these cells, we addressed the possibility that our differentially expressed genes could be found in the stromal component of lung cancers and, when present, could correlate with worse outcome. Kaplan-Meier survival analysis of lung squamous cell and adenocarcinoma patients clustered into 2 groups according to expression of downregulated genes in pregnant mouse lung indicated that our signature performs well in predicting outcome. This observation is consistent with our previous work on a purely stromal cell-derived signature associated with invasive prostate cancer that was able to segregate primary prostate cancer samples with good prognosis from those with poor prognosis (47) . Analysis of mean fold change in lung cancer samples revealed that the majority of downregulated genes in pregnant mouse lung were also less expressed in samples of patients clustering into the poor-prognosis group, which suggests that these genes may have metastasis and primary tumor suppressor functions when expressed by stromal cells.
In conclusion, we postulate that the many previously reported similarities in molecular and cellular mechanisms involved in cancer progression and placentation (48) should be extended to include a common mechanism for increasing permissiveness to metastasis in target organs by a process that involves, at least in part, accumulation of MDSCs and suppression of NK cell activity. MDSC accumulation has not to our knowledge been invoked previously in the context of pregnancy, but may well be a means whereby uterine as well as systemic maternal immune tolerance are regulated.
Methods
Animals. Female standard and cg KO NOD/SCID mice were obtained from in-house breeding at the ISREC mouse facility. C57BL/6 mice were from Jackson Laboratories, A/JOIaHsd mice from Harlan Laboratories. Female mice were between 8 and 10 weeks old at the beginning of experiments. Pregnancy was timed by checking for vaginal plugs early mornings for 4 days after setting up breeding couples. Experiments involving mice were approved by the Etat de Vaud, Service Vétérinaire (Epalinges, Switzerland; authorization no. VD1477.1)
Reagents. The antibodies used were as follows: anti-ER MAb (RTU-ER-6F11) from Novocastra; anti-PR MAb (PgR 63) and anti-human Ki67 MAb (M7240) from DakoCytomation; anti-GFP MAb (11 814 460 001) from Roche; rat anti-mouse CD11b-PE (M1/70), hamster anti-mouse CD49b-PE (HMα2), rat anti-mouse CD16/32 (2.4G2), rat anti-mouse IL-2 (clone JES6-5H4), rat anti-mouse IL-10 (JES5-16E3), and rat anti-mouse IFN-γ (XMG1.2) from BD Biosciences -Pharmingen; rat anti-mouse NKG2D-APC (CX5), rat anti-mouse NKp46-Alexa Fluor 647 (29A1.4), and mouse anti-mouse NK1.1-APC (PK136) from eBioscience; rat anti-mouse CD45-PE-Cy7 (30-F11) from BioLegend; rat anti-mouse Gr-1-FITC (Ly-6G/Ly-6C; RB6-8C5) from BioLegend and BioXCell (for in vivo depletion); rabbit AAGM1 from WAKO; and appropriate isotype controls and HRP-conjugated secondary antibodies. poly(I:C) was from Sigma-Aldrich). d-luciferin (firefly) potassium salt was from Biosynth. MACS cell sorting reagents were as follows: anti-CD49b-conjugated magnetic microbeads (DX5) and biotinylated anti-Ly-6G (1A8) antibody with anti-biotin-conjugated magnetic microbeads (Miltenyi Biotec). Collagenase II from Clostridium histolyticum was from Sigma-Aldrich. Recombinant human IL-2 was from ImmunoTools. Baytril antibiotics, 10% oral solution, were from Bayer.
Luciferase and GFP transduction of tumor cells. cDNA encoding firefly luciferase (from pGL3) and enhanced GFP were cloned into second-generation lentivectors containing a EF1α or CMV promoter and puromycin or hygromycin selection markers. B16.F10, LLC, TA3, HT1080, and MDA-MB-435 cells were cultured in DMEM supplemented with 10% FBS. RMA, EL4, and Yac-1 cells were maintained in RPMI-1640 supplemented with 10% FBS.
Tumor cell injection, tumor resection, and adoptive transfer of MDSCs. For tail vein or s.c. injections, subconfluent tumor cells were detached with EDTA, washed, and resuspended in DMEM. For spontaneous metastasis assay, primary tumors (8-9 mm largest diameter) were resected 11 days after s.c. injection under general anesthesia. For MDSC adoptive transfer, cells were isolated with anti-Ly-6G microbeads, washed in PBS, and injected (6 × 10 6 cells per animal) into the tail vein 20 hours prior to tumor cell injection. At least 5 animals per condition were used. Results shown are representative of at least 2 independent experiments.
Sublethal irradiation and NK cell and MDSC depletion. Sublethal γ irradiation of virgin and 14-day pregnant NOD/SCID mice was performed using a 137 Cs source (1.6 Gy/min), and irradiation time was adjusted to reach a total dose of 2.7-3.0 Gy per animal. For NK cell depletion, rabbit AAGM1 (~400 μg) was injected i.v. 4 and 2 days prior to B16.F10 tail vein injection. Depletion efficiency was tested by flow cytometry of blood samples. For MDSC depletion, anti-Gr-1 antibody (RB6-8C5; 250 μg per injection) was injected into the tail vein of virgin and pregnant mice, 3 and 1 days prior to tumor cell injection and 1 day later. Depletion efficiency was assessed on blood smears. For NK cell and MDSC depletion, appropriate control Igs -rabbit IgG and rIgG2b (clone LTF2), respectively -were injected into control animals. All animals were given antibiotic prophylaxis (300 μl Baytril in 250 ml drinking water).
Immunohistochemistry, lung histomorphometry, and blood leukocyte enumeration. Formalin-fixed, paraffin-embedded lung tissue was stained for GFP, hKi67, ER, and PR according to the manufacturer's recommendations. H&E staining was done according to standard procedures. 4-5 fields of 1 H&E-stained lung section per animal were photographed at ×20 magnification, and the percentage of lung surface occupied by metastatic lesions was determined as a pixel ratio in Photoshop CS. For quantification of leukocytes, mouse blood (cardiac or tail vein) was collected into 1.2 ml EDTA monovette tubes (Sarstedt) and diluted 1:20 in Leukoplate (SOBODIA) before counting in a Neubauer chamber. Blood smears were stained with Giemsa-Wright (HemoQuick; Labo Moderne).
Mouse serum and plasma extraction and proliferation assay. Blood was obtained from pregnant and virgin mice by cardiac puncture. For serum extraction, whole blood was left to coagulate at room temperature for 15 minutes, then spun at 1,000 g for 15 minutes. For plasma preparation, blood was collected in a syringe containing 10 IE liquemin (Roche), diluted 1:1 with serum-free medium, and then spun at 1,500 g for 15 minutes. 3 × 10 3 B16.F10, HT1080, and MDA-MB-435 cells were seeded into wells of a 96-well plate 24 hours before the assay and serum-starved overnight. Mouse serum and plasma were diluted to 15% in serum-free medium and added to the tumor cells. MTT assay (Promega) was performed according to the product protocol after 48 hours of incubation. Serum from 3 different mice was used per condition, and the experiment was conducted in triplicates for each cell line and serum. Plasma was prepared from 1 mouse per condition in duplicate wells.
Fluorescence stereomicroscopy. Mouse lungs were excised at given time points after tail vein injection of GFP-expressing tumor cells and immediately visualized under a Leica MZ16 1FA fluorescence stereomicroscope with a fixed exposure time to compare pictures from pregnant and virgin mouse lungs.
In vivo bioluminescence imaging. After tail vein injection of luciferase-expressing tumor cells, total tumor cell load was assessed at various intervals by bioluminescence imaging in an IVIS 200 series system (Xenogen) after i.p. luciferin
